Belief BioMed's Gene Therapy for DMD Receives Orphan Drug Designation & Rare Pediatric Disease Designation from the U.S. FDA

Great news! The gene therapy for hemophilia B developed by Belief BioMed has received Advanced Therapy Medicinal Product Designation from the EMA!

Belief BioMed to Collaborate with AskBio to Explore the Potential of New Gene Therapies

Belief BioMed’s New Drug Application for BBM-H901, a gene therapy product for hemophilia B, has been accepted by the National Medical Products Administration of China

Good News | Belief BioMed Successfully Completed Dosing of First Subject in the Registrational Clinical Trial for Hemophilia A

Belief BioMed and Takeda China Announced Exclusive Commercial Partnership in the Field of Hemophilia B，Bringing Innovative Gene Therapy to Chinese Patients

Belief BioMed Announces a Key Milestone of Dosing Completion for All Subjects in its Registrational Clinical Trial of BBM-H901

Belief BioMed’s Second AAV-based Gene Therapy Drug Candidate was Granted Orphan Drug Designation by the FDA

The Case Report of Belief BioMed’s Hemophilia B Gene Therapy Drug Candidate BBM-H901 Published in The New England Journal of Medicine

Belief BioMed’s AAV-based Gene Therapy Drug Candidate Receives China CDE’s Breakthrough Therapy Designation

Belief BioMed’s AAV-based Gene Therapy Drug Candidate was Granted Orphan Drug Designation by the FDA

Belief BioMed Co-Founder and CEO Dr. Jane Zheng was Selected by Forbes as One of the "50 Chinese Women in Science and Technology"!

Clinical Trial Results of Belief BioMed's Hemophilia B Gene Therapy Drug Candidate BBM-H901 Published in The Lancet Haematology

Belief BioMed Completed Dosing of the First Subject in the Registrational Gene Therapy Clinical Trial for Hemophilia B

Remarkable success once more! Belief BioMed won the award of "the 10th China Innovation and Entrepreneurship Competition Excellent Enterprise"

2021 Future Medical Industry Summit, Dr. Xiao Xiao【Gene Therapy: Expansion from Rare Disease to Common Medicine】

Belief Biomed’s Gene Therapy for Hemophilia B Receives NMPA IND Approval: First Intravenous Infusion Gene Therapy for Rare Disease in China

Belief BioMed and China Chord Rare Disease Center held a meeting in Minhang, Shanghai

Belief BioMed announced the opening of new development & manufacturing center in Minhang Shanghai

Belief BioMed seized the new developing opportunity of Lin-gang and signed a contract to construct the key project in Lin-gang Biotechnology Industrial Park

The 8th China Rare Disease Summit

Belief BioMed Invests Over 100 million RMB to Construct a State-Of-The-Art Gene Therapy Manufacturing plant in Minhang Shanghai.